Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 1997

View Archived Issues

Novel antiangiogenic compounds from ADIR

Nissan Chemical discloses novel cardiovascular agents

Mitotix reports antiviral/anticancer antisense constructs

Novel human serine protease inhibitor for pancreatitis claimed by Incyte

T Cell Sciences describes anti-CETP vaccines

Anti-gp130 MAbs for inflammatory disorders and myeloma

Antidementia agents reported by Eisai

U.S. IND granted for Scotia's photodynamic drug

Pilocarpine TDS shows antiglaucoma activity in patients

University of Arizona researchers developing potential AD diagnostic

Lansoprazole equieffective to omeprazole in Dutch trial

Once-daily oral antibiotic from RPR cleared by FDA

Debate centers on the safety of coated aspirin

Immunomodulatory effects of ranitidine assessed in patient studies

Beacon signs Japanese licensing agreement for HIV and hepatitis tests

Company Profile: Cadila Pharmaceuticals

Hoechst establishes diagnostics company

Company Profile: Emisphere Technologies

Roche to acquire RPR consumer products

Crinone efficacy equal to that of higher doses of oral progesterone in IVF procedures

Novo Nordisk clear to market hGH product in U.S.

Osiris provides funds for clinical trial of hMSCs

Norian begins trial of Norian SRS in hip fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...